Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.

Heather A. Wakelee, Joan H. Schiller

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The treatment of lung cancer remains a significant challenge. Although chemotherapy remains the standard approach, a plateau has been reached in its efficacy. The development of novel targeted agents, particularly those targeting the epidermal growth factor receptor, has given us another approach. Developments with antiangiogenesis agents hold promise as new approaches in lung cancer therapy. Much of the work to date has focused on the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab. In this article we will focus on the tyrosine kinase inhibitors of the VEGF receptors. These compounds, including sunitinib (SU11248; Sutent), vatalanib (PTK787), ZD6474, AZD2171, GW786034, sorafenib (BAY 43-9006), CP-547,632, and AG013736, are still at an early stage of development. We present phase I data (and phase II/III data when available) of these compounds and discuss their potential development in the treatment of lung cancer.

Original languageEnglish (US)
JournalClinical lung cancer.
Volume7 Suppl 1
StatePublished - Sep 2005

Fingerprint

Vascular Endothelial Growth Factor Receptor
Lung Neoplasms
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Therapeutics
Drug Therapy
Antibodies
sunitinib
sorafenib
vatalanib

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors : novel agents with potential in lung cancer. / Wakelee, Heather A.; Schiller, Joan H.

In: Clinical lung cancer., Vol. 7 Suppl 1, 09.2005.

Research output: Contribution to journalArticle

@article{45a9d10504d44d20ac4db03063f41888,
title = "Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.",
abstract = "The treatment of lung cancer remains a significant challenge. Although chemotherapy remains the standard approach, a plateau has been reached in its efficacy. The development of novel targeted agents, particularly those targeting the epidermal growth factor receptor, has given us another approach. Developments with antiangiogenesis agents hold promise as new approaches in lung cancer therapy. Much of the work to date has focused on the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab. In this article we will focus on the tyrosine kinase inhibitors of the VEGF receptors. These compounds, including sunitinib (SU11248; Sutent), vatalanib (PTK787), ZD6474, AZD2171, GW786034, sorafenib (BAY 43-9006), CP-547,632, and AG013736, are still at an early stage of development. We present phase I data (and phase II/III data when available) of these compounds and discuss their potential development in the treatment of lung cancer.",
author = "Wakelee, {Heather A.} and Schiller, {Joan H.}",
year = "2005",
month = "9",
language = "English (US)",
volume = "7 Suppl 1",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",

}

TY - JOUR

T1 - Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors

T2 - novel agents with potential in lung cancer.

AU - Wakelee, Heather A.

AU - Schiller, Joan H.

PY - 2005/9

Y1 - 2005/9

N2 - The treatment of lung cancer remains a significant challenge. Although chemotherapy remains the standard approach, a plateau has been reached in its efficacy. The development of novel targeted agents, particularly those targeting the epidermal growth factor receptor, has given us another approach. Developments with antiangiogenesis agents hold promise as new approaches in lung cancer therapy. Much of the work to date has focused on the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab. In this article we will focus on the tyrosine kinase inhibitors of the VEGF receptors. These compounds, including sunitinib (SU11248; Sutent), vatalanib (PTK787), ZD6474, AZD2171, GW786034, sorafenib (BAY 43-9006), CP-547,632, and AG013736, are still at an early stage of development. We present phase I data (and phase II/III data when available) of these compounds and discuss their potential development in the treatment of lung cancer.

AB - The treatment of lung cancer remains a significant challenge. Although chemotherapy remains the standard approach, a plateau has been reached in its efficacy. The development of novel targeted agents, particularly those targeting the epidermal growth factor receptor, has given us another approach. Developments with antiangiogenesis agents hold promise as new approaches in lung cancer therapy. Much of the work to date has focused on the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab. In this article we will focus on the tyrosine kinase inhibitors of the VEGF receptors. These compounds, including sunitinib (SU11248; Sutent), vatalanib (PTK787), ZD6474, AZD2171, GW786034, sorafenib (BAY 43-9006), CP-547,632, and AG013736, are still at an early stage of development. We present phase I data (and phase II/III data when available) of these compounds and discuss their potential development in the treatment of lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=33644618100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644618100&partnerID=8YFLogxK

M3 - Article

C2 - 16159417

AN - SCOPUS:33644618100

VL - 7 Suppl 1

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -